Iowanews Headlines

DelveInsight’s, “Vitiligo Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Vitiligo pipeline landscape. It covers the Vitiligo pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vitiligo pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Vitiligo Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Vitiligo Pipeline Outlook Report

Key Takeaways from the Vitiligo Pipeline Report

• On 20 November 2025, Incyte Corporation announced a Phase 3 study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
• On 17 November 2025, National Institute of Allergy and Infectious Diseases (NIAID) conducted a study is designed to evaluate the efficacy of AMG 714 for the treatment of adult participants with vitiligo.
• On 10 November 2025, AbbVie conducted a study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo (NSV). Adverse effects and change in disease activity will be assessed.
• On 10 November 2025, Takeda initiated a study is to learn how safe dacomitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to zasocitinib after about 6 months.
• DelveInsight’s Vitiligo pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Vitiligo treatment.
• The leading Vitiligo Companies such as Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others.
• Promising Vitiligo Pipeline Therapies such as Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others.

Discover how the Vitiligo treatment paradigm is evolving. Access DelveInsight’s in-depth Vitiligo Pipeline Analysis for a closer look at promising breakthroughs @ Vitiligo Clinical Trials and Studies

Vitiligo Emerging Drugs Profile

• Povorcitinib: Incyte Corporation

Povorcitinib (INCB54707) is an oral, selective JAK1 inhibitor developed by Incyte as a potential treatment for vitiligo. It works by targeting the JAK-STAT signaling pathway, which is involved in the immune system’s attack on melanocytes, the pigment-producing cells in the skin. By inhibiting JAK1, Povorcitinib aims to reduce inflammation and halt the immune-mediated destruction of melanocytes, thereby promoting repigmentation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Vitiligo.

• VYN201: Vyne Therapeutics Inc.

VYN201 (Repibresib) is a locally administered pan-BET inhibitor designed to target multiple inflammatory signaling pathways with minimal systemic exposure. It binds to both BD1 and BD2 bromodomains, offering broad anti-inflammatory activity. Its soft drug design allows for targeted treatment of conditions like vitiligo while minimizing systemic side effects. Repibresib shows potential for other inflammatory skin disorders benefiting from localized therapy. Currently, the drug is being evaluated in Phase II stage of its clinical trial for the treatment of Vitiligo.

• MK-6194: Merck Sharp & Dohme LLC

MK-6194 is an investigational IL-2 mutein, a modified form of interleukin-2 designed to selectively activate regulatory T cells (Tregs). It is being studied as a potential treatment for non-segmental vitiligo, a condition where patches of skin lose their pigment. By boosting Treg activity, MK-6194 aims to help control the autoimmune response that contributes to pigment loss. This targeted approach may support repigmentation and reduce the extent of vitiligo patches. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Vitiligo.

The Vitiligo Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Vitiligo with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Vitiligo Treatment.
• Vitiligo Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Vitiligo Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Vitiligo market.

Get a detailed analysis of the latest innovations in the Vitiligo pipeline. Explore DelveInsight’s expert-driven report today! @ Vitiligo Unmet Needs

Vitiligo Companies

Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others.

Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Vitiligo Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Vitiligo Therapies and key Developments @ Vitiligo Market Drivers and Barriers, and Future Perspectives

Scope of the Vitiligo Pipeline Report

• Coverage- Global
• Vitiligo Companies- Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others.
• Vitiligo Pipeline Therapies-Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others.
• Vitiligo Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Vitiligo Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Vitiligo drug development? Find out in DelveInsight’s exclusive Vitiligo Pipeline Report—access it now! @ Vitiligo Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Vitiligo: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Vitiligo– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Afamelanotide: Clinuvel, Inc.
9. Mid Stage Products (Phase II)
10. VYN201: Vyne Therapeutics Inc.
11. Early Stage Products (Phase I)
12. FB102: Forte Biosciences, Inc.
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Vitiligo Key Companies
17. Vitiligo Key Products
18. Vitiligo- Unmet Needs
19. Vitiligo- Market Drivers and Barriers
20. Vitiligo- Future Perspectives and Conclusion
21. Vitiligo Analyst Views
22. Vitiligo Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/vitiligo-pipeline-insight